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Abstract
Background: Common variable immunodeficiency (CVID) 
is the most frequent primary immunodeficiency disorder 
mainly characterized by recurrent bacterial infections be-
sides other immunological defects including loss of or dys-
function of B cells and decreased immunoglobulin levels. In 
this study, our aim is to evaluate clinical, immunological, and 
molecular data of patients with a primary clinical diagnosis 
of CVID and autoimmune phenotype with a confirmed ge-
netic diagnosis. Methods: Among 297 patients with CVID, 
who were registered in the Iranian Primary Immunodeficien-
cy Registry at Children’s Medical Center Hospital in Iran, 83 
patients have been genetically examined and 27 patients 
with autoimmunity and confirmed genetic mutations were 
selected for analysis. Whole-exome sequencing and confir-
matory Sanger sequencing methods were used for the study 
population. A questionnaire was retrospectively filled for all 
patients to evaluate demographic, laboratory, clinical, and 
genetic data. Results: In the 27 studied patients, 11 different 
genetic defects were identified, and the most common mu-
tated gene was LRBA, reported in 17 (63.0%) patients. Two 
patients (7.7%) showed autoimmune complications as the 
first presentation of immunodeficiency. Eleven patients 
(40.7%) developed one type of autoimmunity, and 16 pa-
tients (59.3%) progressed to poly-autoimmunity. Most of the 
patients with mono-autoimmunity (n = 9, 90.0%) primarily 
developed infectious complications, while in patients with 
poly-autoimmunity, the most common first presentation 
was enteropathy (n = 6, 37.6%). In 13 patients (61.9%), the 
diagnosis of autoimmune disorders preceded the diagnosis 
of primary immunodeficiency. The most frequent autoim-
mune manifestations were hematologic (40.7%), gastroin-
testinal (48.1%), rheumatologic (25.9%), and dermatologic 
(22.2%) disorders. Patients with poly-autoimmunity had 
lower regulatory T cells than patients with mono-autoimmu-
nity. Conclusion: In our cohort, the diagnosis of autoim-
mune disorders preceded the diagnosis of primary immuno-
deficiency in most patients. This association highlights the 
fact that patients referring with autoimmune manifestations 
should be evaluated for humoral immunity.
© 2020 S. Karger AG, Basel
Introduction
Common variable immunodeficiency (CVID) is the 
most frequent symptomatic primary immunodeficiency 
mainly characterized by recurrent bacterial infections and 
immune dysregulation. The distribution and prevalence of 
CVID vary between countries. It ranges from 1 in 50,000 
to 1 in 25,000 people in European populations and less fre-
quent in African and East Asian populations [1, 2]. Over 
the past years, quality of life and prognosis for patients with 
CVID have significantly increased due to advances in the 
management and prophylaxis of infection, such as immu-
noglobulin (Ig) replacement and antimicrobial agents 
which are now highly effective at preventing and treating 
infections in many CVID [3]. Having improved in the 
management of infection, autoimmunity is becoming an 
increasing cause of morbidity and mortality [3].
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Although CVID is the diagnosis of exclusion, its clini-
cal diagnosis may mimic by several genetic defects that 
affect different components of the innate and adaptive 
responses associated with autoimmune disorders [4]. 
Different mechanisms have been proposed for autoim-
munity as one of the main complications of CVID; how-
ever, some monogenetic defects, including transmem-
brane activator and calcium-modulating cyclophilin li-
gand interactor (TACI, TNFRSF13B) deficiency, inducible 
T-cell costimulator (ICOS) deficiency, B-cell activating 
factor receptor (BAFF-R, TNFRSF13C) deficiency, muta-
tions in molecules involved in the activation of B-cell re-
ceptor (CD19, CD20, CD21, and CD81), and lipopolysac-
charide-responsive beige-like anchor protein (LRBA) de-
ficiency may predispose patients to autoimmunity and 
immune dysregulation [5]. Although autoimmunity and 
immunodeficiency were previously thought to be two 
ends of a spectrum, an increased understanding of the 
complex immune regulatory and signaling mechanisms 
involved, coupled with the application of genetic analysis, 
is revealing the complex association of some specific 
genes underlying CVID with autoimmune phenotype [6]. 
Many autoimmune manifestations are prevalent in CVID 
cohorts across a range of monogenic forms of CVID [3]. 
Autoimmunity is present in 20–30% of CVID patients [5, 
7]. The 2 most prominent autoimmunities in CVID are 
idiopathic thrombocytopenic purpura (ITP) (10–12%) 
and autoimmune hemolytic anemia (AIHA) (5–7%), 
which are commonly correlated with splenomegaly [5, 7]. 
Occasionally, the onset of autoimmune cytopenia is ear-
lier than the diagnosis of CVID, so the differential diag-
nosis of humoral immunodeficiency with adult onset 
should be considered by hematologists [7]. Autoimmune 
cytopenias associated with CVID have some immunolog-
ical indicators including low numbers of class-switched 
memory B cells, expanded CD21low B cells, and low num-
bers of regulatory T cells (Tregs). Other autoimmunities 
including vitiligo, thyroid disorders, psoriasis, pernicious 
anemia, systemic lupus erythematosus, and rheumatoid 
arthritis (RA) have been reported in CVID patients [5]. 
In this study, our aim is to evaluate clinical, immunolog-
ical, and molecular data of monogenic patients with a 
clinical diagnosis of CVID and autoimmune phenotype.
Patients and Methods
Patients
A total of 297 patients with CVID were registered by expert 
clinical immunologists in the Iranian Primary Immunodeficiency 
Registry (IPIDR) at Children’s Medical Center Hospital in Iran [8] 
on the basis of updated diagnostic criteria recommended by the 
European Society for Immunodeficiencies (ESID) [9]. Among 83 
registered patients with an initial diagnosis of CVID with known 
gene mutations, a total of 27 patients with autoimmunity and con-
firmed genetic mutations were selected for analysis [10, 11]. The 
study was approved by the Ethics Committee of the National In-
stitute for Medical Research Development.
Mutation Analysis
Whole peripheral blood samples were taken from our study 
population, and genomic DNA extraction was performed for the 
available patients with a tentative diagnosis of CVID and autoim-
mune phenotype. The whole-exome sequencing and confirma-
tory Sanger sequencing methods were carried out according to a 
pipeline published previously [10, 11]. The pathogenicity of all 
disease-attributable gene variants was re-evaluated using the up-
dated guideline for interpretation of molecular sequencing by the 
American College of Medical Genetics and Genomics (ACMG) 
[12].
Data Collection
A questionnaire was retrospectively filled by reviewing medi-
cal records and the IPIDR database for those patients with a con-
firmed molecular diagnosis, and if possible, data were updated by 
direct interviews of these selected patients to collect information 
including demographic data, clinical manifestations, medical his-
tory, physical examination, laboratory and molecular findings, 
and mortality. We investigated demographic data such as age, 
gender, age at disease onset, age at diagnosis, and delay of diagno-
sis. Laboratory data were recorded including complete cell blood 
count, T-cell and B-cell subsets (was assessed using flow cytom-
etry analysis), serum levels of immunoglobulins (was assessed us-
ing nephelometry and enzyme-linked immunosorbent assay), 
and autoantibodies as described previously [10, 13]. For each pa-
tient, autoimmune complication before and/or after diagnosis 
was recorded. The diagnosis of autoimmunity was confirmed by 
a combination of clinical manifestations and complementary 
paraclinical findings including the pathology results of the biopsy 
taken over endoscopy and/or colonoscopy and radiologic studies 
based on international criteria. The evaluation for autoimmunity 
diagnosis was reviewed for all patients by an immunologist and a 
subspecialist related to the affected organ as explained previously 
[14]. Patients with incomplete diagnostic criteria or missed data 
were excluded. Medical information was collected after obtaining 
written informed consent from all patients and/or their surro-
gates.
Statistical Analysis
Values were presented as frequency (number and percent-
age), mean ± SD, and median (interquartile range, IQR), as ap-
propriate. Fisher’s exact test and χ2 tests were used for 2 × 2 
comparisons of categorical variables. To compare numerical 
variables, the Mann-Whitney U test was used for nonparametric 
data and t tests were used for parametric data. The Shapiro-Wilk 
test was used to check the assumption of normality for a variable, 
and the parametric or nonparametric tests were carried out ac-
cording to the normality assumption. Statistical analyses were 
performed using the SPSS software package, version 22 (SPSS 




















   
   
   
   
   
   
   
   
   
   
























A total of 27 patients (11 males [40.7%] and 16 females 
[59.3%]) with a mean (SD) age of 16.4 (±8.2) years were 
enrolled in this study (Table 1). The median (IQR) age at 
the onset of symptoms was 2.0 (0.6–3.0) years, and the 
mean (SD) age at the time of diagnosis was 8.3 (±6.0) 
years. The mean (SD) diagnostic delay was 5.7 (±5.2) 
years. Overall, 25 patients (92.6%) were born through 
consanguineous parents. At the time of the study, 8 
(29.6%) individuals were deceased and the median fol-
low-up for survived cases was 15.5 (±7.5) years. During 
the course of the disease, 11 patients (40.7%) were com-
plicated with one type of autoimmunity and 16 patients 
(59.3%) developed poly-autoimmunity (more than one 
type of autoimmunity), of which 68.8% were female. The 
patients’ characteristics are summarized in Table 1.
Genetic analysis as an inclusion criterion for this study 
was confirmed in all recruited 27 patients who were pri-
marily diagnosed with CVID. The pathogenic variants 
were identified in LRBA (n = 17) and DCLRE1C (Arte-
mis), BLNK, BTK, DNMT3B, JAK3, MVK, RAG1, 
SH2DA1, XIAP, and IGHM (µ heavy chain) each in 1 pa-
tient (Table 2).
Clinical Evaluation
As shown in Figure 1, the most prevalent first presen-
tation of immunodeficiency in these patients was an in-
fectious disease (n = 13, 50.0%) and chronic diarrhea 
(n = 7, 26.9%). Also, 2 patients (7.7%) showed autoim-
mune complications including ITP and AIHA, as the first 
clinical manifestation of the disease. In 13 patients 
(61.9%), the diagnosis of autoimmune disorders preced-
ed the diagnosis of primary immunodeficiency, and in 7 
(33.3%) patients, autoimmune complications were iden-
tified during the course of the disease (after diagnosis); 
while in 1 patient, the diagnosis was concurrent.
Gastrointestinal (n = 13, 48.1%), hematologic (n = 11, 
40.7%), dermatologic (n = 6, 22.2%), and rheumatologic 
(n = 7, 25.9%) related autoimmunities were the most 
prevalent autoimmune manifestation in our CVID pa-
tients. Specific autoimmune entities included ITP (40.7%), 
AIHA (29.6%), RA/juvenile idiopathic arthritis (JIA) 
(25.9%), and inflammatory bowel disease (IBD, 22.2%) 






Patients, n 27 11 16 –
Sex ratio (M/F), n 11/16 6/5 5/11 0.26
Age, years 17 (11.0–22.0) 17.0 (6.0–24.0) 18.5 (12.25–21.5) 0.52
Age at onset, years 2.0 (0.6–3.0) 1.25 (0.5–2.25) 2.0 (0.6–4.0) 0.52
Age at diagnosis, years 7.0 (3.75–12.25) 8.0 (3.0–12.0) 7.0 (5.0–13.0) 0.64
Delay in diagnosis, years 5.0 (2.0–7.75) 4.3 (1.6–9.0) 5.0 (2.0–6.0) 0.97
Course of disease, years 15.5 (9.5–19.5) 17.5 (5.7–26.0) 15.0 (10.0–19.0) 0.78
Age at diagnosis of autoimmunity, years 4 (2.2–7) 4.5 (2.0–10.75) 4.0 (2.5–6.0) 0.94
Consanguinity, n (%) 25 (92.6) 10 (90.9) 15 (93.8) 1.0
Dead, n (%) 8 (29.6) 4 (36.4) 4 (25) 0.67













Fig. 1. First presentation of monogenic primary immunodeficien-
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(Fig. 2). In addition, both autoimmune neurologic and 
endocrine disorders were reported in 7.4% of our mono-
genic CVID-like patients.
Among 16 patients with poly-autoimmunity, 10 pa-
tients (62.5%) had 2 types of autoimmunity, 3 patients 
(18.8%) had 3 types of autoimmunity, and 3 patients 
had 4 types of autoimmunity. The most common over-
lapping syndrome was the combination of rheumato-
logic and gastrointestinal autoimmune disorders. In 
addition, the frequency of ITP (62.5 vs. 9.1%, p = 0.008) 
and AIHA (50.0 vs. 0.0%, p = 0.008) was higher than 
that of other autoimmune manifestations in patients 
with poly-autoimmunity than those with mono-auto-
immunity.
Most of the patients with mono-autoimmunity pri-
marily developed infectious complications including 
pneumonia (n = 4) and sinusitis (n = 2). While in patients 
with poly-autoimmunity, the most common first presen-
tation was chronic diarrhea (n = 6). As illustrated in Ta-
ble 3, the frequency of otitis media, sinusitis, pneumonia, 
skin infection, septicemia, bronchiectasis, failure to 
thrive, splenomegaly, hepatomegaly, clubbing, enteropa-
thy, and allergy/asthma were reported more frequently 
in patients with poly-autoimmunity than mono-autoim-
munity; however, the differences were not significant. 
Mortality was reported in 4 patients with poly-autoim-
munity and in 4 patients with mono-autoimmunity.
Immunological Evaluation
The summary of immunological findings is represent-
ed in Table  4. Overall, lymphopenia was reported in 
38.5% of patients. While most of the patients had a nor-
mal (66.7%) or elevated (29.2%) level of CD3+ T lympho-
cyte, 34.8% of patients had low CD19+ B lymphocytes. A 
low frequency of CD4+ T cells and a high frequency of 
CD8+ T cells were reported in 40.0 and 37.5% of patients, 
respectively. There was no statistical difference in immu-
noglobulin levels and B-cell and T-cell counts in CVID 
patients with or without poly-autoimmunity. The num-
ber of Treg cells was decreased in all poly-autoimmune 
patients, while 66.7% of patients with mono-autoimmu-
nity had a low number of Treg cells.
Discussion
Autoimmune diseases can affect all subgroup classifi-
cations of primary immunodeficiency but are more fre-
quently encountered in predominantly antibody defects, 
particularly CVID in which more than 20–30% of affect-
ed patients tend to develop autoimmune manifestations 
[3, 15]. Based on the ESID criteria, our patients were pri-
marily diagnosed with CVID, but after genetic analysis 
via whole-exome sequencing, some patients with genetic 
defects in nonintrinsic B-cell pathways can be categorized 
as having combined immunodeficiency (CID) which 
presents the mild phenotype of the disease.
In our study, the first presentation of 7.7% of the se-
lected group of CVID patients was autoimmunity, and in 
61.9% of CVID patients, the diagnosis of autoimmune 
disorders preceded the diagnosis of immunodeficiency. 
Therefore, autoimmunity may be an alarming sign of the 
disease in pediatric CVID patients with no considerable 
history of severe and recurrent infections. Moreover, au-
toimmune disorders seem to be one of the first presenta-
tions of the monogenic forms of humoral immune disor-
ders. It is crucial for physicians to be alerted about the 
main manifestations of CVID in order to reduce the di-
agnostic delay and establish timely Ig replacement thera-
py in these patients.
Autoimmune cytopenias are the most common organ-
















Fig. 2. Autoimmune complications reported in CVID patients. 
CVID, common variable immunodeficiency; ITP, idiopathic 
thrombocytopenic purpura; AIHA, autoimmune hemolytic ane-
mia; RA, rheumatoid arthritis; JRA, juvenile rheumatoid arthritis; 
JIA, juvenile idiopathic arthritis; IBD, inflammatory bowel disease; 
AIE, autoimmune enteropathy; AIT, autoimmune thyroiditis; 
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munodeficiency, and reports suggest that these disorders 
are subsequently diagnosed in up to 50% of pediatric cas-
es of refractory multilineage autoimmune cytopenia [16, 
17]. ITP is the most common cytopenia followed by 
AIHA in patients with humoral immunodeficiency [18]. 
Some patients have both ITP and AIHA, a condition of-
ten referred to as Evans syndrome. In one large case series 
of patients with CVID, the incidence of ITP was reported 
to be 14.2%, AIHA, 7%, Evans syndrome, 4%, and auto-
immune neutropenia, <1% [19]. This high prevalence of 
hematologic autoimmune manifestations in PID was also 
apparent within our cohort with 40.7% of participants de-
veloping hematologic autoimmune complications, in-
cluding ITP (40.7%) and AIHA (29.6%); however, Evans 
syndrome as another hematologic autoimmune compli-
cation was mentioned for only 1 patient. This high level 
of association highlights the fact that patients referring to 
autoimmune cytopenia particularly those with a “diffi-
cult-to-treat” ITP or AIHA should be evaluated for hu-
moral immunity.
It was reported that about 25% of patients with au-
toimmune diseases have a tendency to develop addi-








ITP 11 (40.7%) 1 (9.1%) 10 (62.5%) 0.008*
AIHA 8 (29.6%) 0 (0.0%) 8 (50%) 0.008*
AIE 4 (14.8%) 1 (9.1%) 3 (18.8%) 0.62
RA/JRA/JIA 7 (25.9%) 3 (27.3%) 4 (25%) 1.0
AIT 2 (7.4%) 0 (0.0%) 2 (12.5%) 0.49
Vitiligo 3 (11.1%) 2 (18.2%) 1 (6.3%) 0.54
Celiac 4 (14.8%) 2 (18.2%) 2 (12.5%) 1.0
Alopecia 2 (7.4%) 1 (9.1%) 1 (6.3%) 1.0
IBD 6 (22.2%) 1 (9.1%) 5 (31.3%) 0.35
MG 1 (3.7%) 0 (0.0%) 1 (6.3%) 1.0
Psoriasis 1 (3.7%) 0 (0.0%) 1 (6.3%) 1.0
Evans syndrome 1 (3.7%) 0 (0.0%) 1 (6.3%) 1.0
MS 1 (3.7%) 0 (0.0%) 1 (6.3%) 1.0
AIH 1 (3.7%) 0 (0.0%) 1 (6.3%) 1.0
Otitis media 17 (63%) 5 (45.5%) 12 (75%) 0.22
Sinusitis 17 (63%) 6 (54.5%) 11 (68.8%) 0.68
Pneumonia 21 (77.8%) 8 (72.7%) 13 (81.3%) 0.66
Skin infection 4 (14.8%) 0 (0.0%) 4 (25%) 0.12
Candidiasis 7 (25.9%) 3 (27.3%) 4 (25%) 1.0
Conjunctivitis 8 (29.6%) 3 (27.3%) 5 (31.3%) 1.0
Meningitis 7 (25.9%) 4 (36.4%) 3 (18.8%) 0.39
Septicemia 2 (7.4%) 0 (0.0%) 2 (12.5%) 0.49
Septic arthritis 6 (22.2%) 3 (27.3%) 3 (18.8%) 0.66
Bronchiectasis 12 (44.4%) 4 (36.4%) 8 (50%) 0.69
Neutropenia 1 (3.7%) 0 (0.0%) 1 (6.3%) 1.0
FTT 4 (14.8%) 1 (9.1%) 3 (18.8%) 0.62
Splenomegaly 15 (55.5%) 5 (45.5%) 10 (62.5%) 0.45
Hepatomegaly 13 (48.1%) 3 (27.3%) 10 (62.5%) 0.12
Lymphadenopathy 8 (29.6%) 3 (27.3%) 5 (31.3%) 1.0
Clubbing 6 (22.2%) 1 (9.1%) 5 (31.3%) 0.35
Malignancy 1 (3.7%) 1 (9.1%) 0 (0.0%) 0.40
Enteropathy 22 (81.5%) 8 (72.7%) 14 (87.5%) 0.37
Allergy/asthma 10 (37.4%) 3 (27.3%) 7 (43.8%) 0.44
ITP, idiopathic thrombocytopenic purpura; AIHA, autoimmune hemolytic anemia; RA, rheumatoid arthritis; 
JRA, juvenile rheumatoid arthritis; JIA, juvenile idiopathic arthritis; IBD, inflammatory bowel disease; AIE, au-
toimmune enteropathy; AIT, autoimmune thyroiditis; MG, myasthenia gravis; MS, multiple sclerosis; AIH, au-
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tional autoimmune diseases [20]. In “multiple autoim-
mune syndromes,” patients often have at least 1 derma-
tological condition commonly alopecia areata or vitiligo 
[21]. In our study among monogenic patients, 59.3% 
had poly-autoimmunity. In contrast to conventional 
“multiple autoimmune syndromes” which usually de-
velops dermatological condition [21], ITP and AIHA 
were the most 2 concomitant autoimmune disorders in 
our monogenic patients. The high frequency of autoim-
mune cytopenias in gene-specific defects was also re-
ported in previous studies, especially in patients with 
LRBA deficiency [22, 23]. Our result showed that 58.8% 
of patients with LRBA deficiency have poly-autoimmu-
nity. It is in line with our previous study that showed 
62.5% of LRBA-deficient patients had poly-autoimmu-
nity [22]. In these patients, autoimmune cytopenias 
were the most frequent complication. Finally, in young 
patients with poly-autoimmunity and enteropathy with 
a history of chronic infection or hypogammaglobu-
linemia, the probability of LRBA deficiency must be 
considered by clinical immunologists.
Conclusion
The identification of an increasing number of genetic 
defects that are associated with autoimmunity and pri-
mary humoral immunodeficiency is providing insight 
into molecular pathways and mechanisms that promote 
immune dysregulation. Early recognition and treatment 
of these symptoms are critical for optimizing the quality 
of life and decreasing complications associated with 
CVID. This requires that patients and their care provid-
ers be aware of signs and symptoms that may suggest an 
autoimmune disease and that appropriate diagnostic 
testing and treatment be initiated in a timely fashion. 
ITP, AIHA, and autoimmune enteropathy are of the 
most prevalent features of monogenic defects resembling 
CVID, especially in patients with a positive family his-
tory of immunodeficiency, parental consanguinity, and/
or recurrent infections. Two clinical clues that may sug-
gest poly-autoimmunity in a patient with PID are either 
the development of autoimmune disorder at an early age 
or a low number of Tregs. Autoimmunity carries high 
morbidity and mortality in patients with CVID; there-
fore, awareness of these monogenic forms of poly-auto-
immunity together with the implementation of precision 
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